The Centers for Medicare & Medicaid Services (CMS) revoked Theranos’ certification for a blood testing laboratory in California and prohibited the embattled company’s CEO Elizabeth Holmes from owning, operating or directing a laboratory for at least two years.

Since Joseph Papa took over as CEO of Valeant Pharmaceuticals, the company’s stock price has fallen by approximately 40 percent, the Wall Street Journal reports. The newspaper speculates one reason for the decrease may be Papa’s strategy while he ran Perrigo Co.

Shares of Esperion Therapeutics’ common stock have plunged this week after the company said the future of its investigational cholesterol-lowering drug remains murky. The FDA told the company that it might require a cardiovascular outcomes study before approving the medication, according to Forbes.

The Medicines Company completed its divestiture of three cardiovascular medications to Chiesi USA, Inc. on June 21, one month after the companies agreed to the deal.

Medtronic raised its quarterly cash dividend 13 percent on June 24 to $0.43 per ordinary share.

Medtronic agreed to acquire HeartWare International Inc. on June 27 for approximately $1.1 billion.

In the wake of Theranos voiding two years of reports from its Edison blood testing devices, Walgreens has decided to terminate its partnership in lab testing at more than 40 Walgreens locations in Arizona.

Valeant Pharmaceuticals agreed to pay $54 million to settle a civil lawsuit, Reuters reports. The U.S. Department of Justice (DOJ) announced on June 9 that the agreement between the government and Valeant pertains to allegations against Salix Pharmaceuticals, which Valeant acquired in April 2015.